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Anti-IT is an unusual specificity originally described as a naturally 
occurring cold agglutinin. The antibody reacts strongly with cord 
RBCs, weakly with adult I RBCs, and most weakly with the rare 
adult i RBCs. IgG anti-IT in patients with hemolytic anemia has 
been associated with Hodgkin’s lymphoma. Difficulties in blood 
grouping tests and the presence of a warm reactive agglutinin in 
samples from two patients with hemolytic anemia led to further 
serologic studies and the identification of anti-IT. In both cases, 
the anti-IT was a rarely encountered IgM warm reactive aggluti-
nin; in one case, the IgG component was also anti-IT, whereas in 
the second case the IgG antibody was broadly reactive. The un-
usual serologic finding of anti-IT prompted further clinical evalu-
ation for lymphoproliferative disease in these two patients. 
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Anti-I
T was originally described as a benign, naturally 
occurring, IgM cold agglutinin in Melanesians1 and 
later in Venezuela Indians.2 The anti-IT agglutinin 
did not demonstrate classical I or i specificity but reacted 
strongly with cord RBCs, weakly with normal adult I RBCs, 
and most weakly with the rare adult i RBCs. It was thought 
the agglutinin recognized a transition state of i to I, thus the 
designation IT (T for transition).1 Subsequent data do not 
support this hypothesis; IT is expressed nearly as well or as 
well on fetal RBCs ranging in age from 11 to 16 weeks as on 
cord RBCs.3 The biochemical structure of IT is still unclear.
 The first four examples of IgG anti-IT were in sera of 
patients with autoimmune hemolytic anemia (AIHA) and 
Hodgkin’s lymphoma.3,4 Others reported a similar associa-
tion.5 Hafleigh et al.6 found three examples of IgG autoanti-
IT in patients who did not have Hodgkin’s disease or AIHA. 
One example of IgM warm anti-IT and one IgM cold plus 
IgG anti-IT in patients with AIHA were not associated with 
Hodgkin’s disease, but one of the cases was associated with 
non-Hodgkin’s lymphoma.7,8 We report an unusual 37°C 
reactive IgM agglutinin plus an IgG anti-IT9 and a 37°C re-
active IgM agglutinating anti-IT plus broadly reactive IgG 
autoantibody in two patients with hemolytic anemia who 
were subsequently evaluated for lymphoproliferative dis-
ease owing to the specificity of the antibodies reported.
Case Reports
Case 1
 A 69-year-old Hispanic woman presented with pancy-
topenia (WBC = 2.3 × 109/L; Hb = 6.9 g/dL; Hct = 19.1%; 
platelets = 64,000/µL), splenomegaly but no lymphade-
nopathy, and hemolytic anemia (spherocytosis; LDH = 672 
U/L [normal 355–630]; total bilirubin = 2.8 mg/dL [normal 
0.1–1.2]; direct bilirubin = 0.7 mg/dL [normal 0–0.4]). The 
direct antiglobulin test (DAT) was positive. Lymphoma was 
not suspected until after the anti-IT was identified. Comput-
ed tomography (CT) scans showed evidence of large lym-
phoid infiltrates composed of a mixture of small and large 
lymphocytes. Bilateral bone marrow aspiration showed in-
creased lymphocytes but was not diagnostic of lymphoma. 
The patient was empirically treated with steroids and had 
improved hemoglobin and sense of well-being. Steroids 
were tapered. Two and a half months later the patient re-
turned for a splenectomy, which was pathologically nega-
tive for lymphoma. Sections showed lymphoid hyperplasia 
with a benign phenotype consisting of T and B cells with no 
aberrant expression of CD5, CD23, or bcl-2. Serologic stud-
ies at that time showed similar reactivity of anti-IT. Three 
months later, the patient exhibited mild thrombocytopenia 
with slightly elevated LDH. A repeat bone marrow showed 
lymphocytosis suggestive of low-grade B-cell lymphopro-
liferative disease. A year later, after rituximab and other 
chemotherapy, the bone marrow showed atypical lymphoid 
infiltrates. The infiltrates were composed primarily of small 
mature lymphocytes with occasional larger lymphocytes 
noted, most likely representing a lymphoproliferative dis-
order. Flow cytometry showed an entire B-cell population 
that did not express CD20. Less than 3 years after original 
presentation, the patient was transfusion-dependant and 
diagnosed with aplastic anemia. She was discharged to hos-
pice care with end-stage liver disease, lymphoproliferative 
disorder, and hemolytic anemia.
Case 2
 A previously healthy 19-year-old Korean man presented 
to the emergency room with insidious onset of fatigue, short-
ness of breath, dyspnea on exertion, and pallor. Laboratory 
data revealed thrombocytopenia and hemolytic anemia: 
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WBC = 6.8 × 109/L; Hb = 4.6 g/dL; Hct = 12%; platelets 
= 20,000/µL; spherocytes on the peripheral smear; total 
bilirubin = 2.9 mg/dL; direct bilirubin = 0.4 mg/dL; and 
LDH = 539 U/L. The haptoglobin was less than 5.8 mg/
dL. There was no splenomegaly or lymphadenopathy. The 
DAT was positive. An autoanti-IT agglutinin plus a broadly 
reactive IgG autoantibody were identified. After a few days 
on pulse dexamethasone (Decadron) therapy the hemoglo-
bin improved only mildly, and the patient was started on 
a 4-day course of IVIG with recovery of his hemoglobin to 
9.3 g/dL. Because of the association of lymphoma with an-
ti-IT the patient underwent CT scans, bone marrow biopsy, 
and positron emission tomography. There was no evidence 
of malignancy or lymphoproliferative process. During the 
period of a year, the patient had multiple relapses of the 
hemolytic anemia (but not thrombocytopenia), necessi-
tating further treatment with steroids. Rituximab, given 
for the hemolytic process, had no sustained benefit. The 
patient underwent a splenectomy, and both the hemoglo-
bin and platelet count remain normal. There has been no 
evidence of Hodgkin’s disease, lymphoma, or other malig-
nancy in several years of follow-up.
Materials and Methods
 The DAT was performed with anti-human IgG (Ortho 
Clinical Diagnostics, Raritan, NJ) and anti-human C3 (in-
house reagent). A 6% bovine albumin control was tested 
in parallel. The in-house anti-C3 was prepared by inject-
ing rabbits with purified proteins and standardized as 
previously described.10 Before testing, the patients’ RBCs 
were treated with 0.01 M dithiothreitol (DTT) to break 
IgM bonds that cause spontaneous agglutination.11 Eluates 
were prepared from the patients’ RBCs using a commercial 
acid elution kit (Gamma Elu-Kit II, Gamma Biologicals, 
Houston, TX); cold LISS was substituted for the kit wash 
solution.12
 For immunoglobulin classification, samples were treat-
ed with 0.01 M DTT. The agglutinin titer and thermal am-
plitude was determined at 37°C (prewarmed), 30°C, 22°C, 
and 4°C with group O adult I, cord, and adult i RBCs,10 and 
for Case 1, with DTT-treated autologous RBCS. The tests at 
each temperature were set up separately (i.e., using sepa-
rate sets of dilutions) to eliminate potential carryover of 
agglutination. Patients’ sera were also tested by a previous-
ly described serum screen method10 used to characterize 
antibodies in AIHA. Briefly, serum 
was tested with and without 
acidification and the addition 
of fresh normal serum as a 
source of complement, against 
untreated and enzyme-treated 
RBCs at 37°C (prewarmed) and 
20°C. Agglutination results 




 The DAT on DTT-treated RBCs was 3+ with anti-IgG 
and anti-C3; the 6% albumin control was nonreactive. The 
initial titer and thermal amplitude studies showed a 37°C 
agglutinin that reacted to a higher titer with cord RBCs than 
with adult I RBCs. Titration results with adult I, cord i, and 
adult i RBCs (to determine specificity) are shown in Table 1. 
Anomalous results (unexplained high titer) were obtained 
with DTT-treated autologous RBCs: titers of 512 at 37°C, 
1024 at 30°C, 2048 at 22°C, and 8000 at 4°C. An apparent 
anti-I was detected at 4°C (adult I RBC titer of 256, cord 
RBC titer of 64). An acid eluate prepared from the patient’s 
RBCs reacted more strongly with cord RBCs than with adult 
I RBCs at 37°C. After treatment with DTT, the patient’s se-
rum and the eluate did not agglutinate cord RBCs, but re-
acted 1+ and 4+, respectively, at the antiglobulin test with 
anti-IgG. The dilution control (for the abolished aggluti-
nation) reacted 3½ to 4+ with the serum and 1½ + with 
the eluate. Thus, IgM plus IgG anti-IT was demonstrated in 
both the serum and the eluate. In the AIHA serum screen, 
agglutination was observed at 22°C and 37°C similar to that 
in the titration and thermal amplitude studies; a hemolysin 
was also observed with enzyme-treated RBCs at both tem-
peratures, but without a clear preference for either temper-
ature.
Case 2
 The DAT on DTT-treated RBCs was 4+ with anti-IgG 
and anti-C3; the 6% albumin control was nonreactive. In the 
initial titer and thermal amplitude studies, an agglutinin re-
acted at 37°C with cord RBCs; adult I RBCs did not react at 
37°C or 30°C. Titration results with adult I, cord i, and adult i 
RBCs are shown in Table 1. Sufficient autologous RBCs were 
not available. DTT treatment of the patient’s serum abolished 
agglutination with cord RBCs; however, dilutions of DTT-
treated serum tested against adult I and cord RBCs did not 
show a difference in reaction strength of the IgG component. 
Thus, an IgM anti-IT plus a broadly reactive IgG antibody was 
demonstrated in the serum. The eluate contained an IgG an-
tibody suggestive of anti-IT (titer/score versus adult I RBCs 
was 32/42 and versus cord RBCs was 128/55). In the AIHA 
serum screen, untreated RBCs were weakly agglutinated at 
22°C and weakly sensitized at 37°C; enzyme-treated RBCs 
were agglutinated and hemolyzed at both temperatures.
Discussion
Table 1. Titer and thermal amplitude of two examples of anti-IT 
RBCS Case 1 titer (score) at: Case 2 titer (score) at:
37°C 30°C 22°C 4°C 37°C 30°C 22°C 4°C
Adult I 1 (4) 1 (6) 2 (11) 256 (78) 0 0 1 (4) 8 (28)
Cord i 32 (37) 128 (61) 256 (68) 64 (56) 64 (54) 64 (52)-128 
(60)
64 (49) 32 (48)
Adult i 1 (6) 2 (10) 2 (10) NT* 0 1 (4) 1 (5) NT
*NT = not tested
Two cases of IgM warm autoanti-IT
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 IgM warm autoagglutinins reactive at 37°C are an 
unusual subcategory of warm autoimmune hemolytic ane-
mia.10,13 Typically, the patient’s RBCs are spontaneously 
agglutinated, requiring treatment with a sulfhydryl reagent 
such as DTT to resolve ABO and Rh typing and to interpret 
the DAT. The two cases presented here were referred to the 
immunohematology research laboratory for further diag-
nostic testing and characterization of the agglutinin when 
these characteristics were noted by our reference labora-
tory. In both cases the warm agglutinin demonstrated IT 
specificity. Both of our cases also demonstrated an IgG au-
toantibody component; in Case 1, the IgG autoantibody was 
anti-IT.
 We have no explanation for the high titers obtained af-
ter DTT-treatment of the group O autologous RBCs in Case 
1. This may indicate that the patient’s RBCs had greatly 
increased IT expression. When group O untreated, DTT-
treated, and ficin-treated cord RBCs were tested in parallel 
with dilutions of this patient’s anti-IT and another sample 
of anti-IT, no enhancement of reactivity was observed with 
DTT treatment whereas reactivity with ficin-treated RBCs 
was increased as expected by three to four dilutions (data 
not shown). Thus, the DTT treatment should not have af-
fected the autologous RBC test results. The previous sample 
of warm IgM anti-IT associated with AIHA did not aggluti-
nate that patient’s untreated autologous RBCs at 37°C (the 
optimal temperature of reactivity).7
 Anti-IT is an unusual specificity and may not even be 
suspected unless dilutions of the sera are tested with cord i 
and adult i RBCs in parallel with adult I RBCs. In our cases, 
additional titrations to identify the specificity were only 
pursued after the initial increased reactivity with cord RBCs 
was observed. Examples of anti-IT have been reported to be 
IgM cold agglutinins or IgG antibodies optimally reactive 
at 37°C. We are only aware of one reported example of IgM 
warm anti-IT, and that case was not associated with Hodg-
kin’s disease or lymphoma.7 In more than 20 years, we have 
encountered only two other examples of IgM warm reactive 
anti-IT; neither had an IgG component, but both were as-
sociated with a history of lymphoma before the serologic 
workup.
 Determining the specificity of autoantibodies is typical-
ly of academic interest only. In general, serologic results do 
not necessarily prompt a clinical evaluation for lymphoma. 
In both of these cases, the unusual RBC antibody and the 
historic association of this specificity with lymphoma, to-
gether with the presenting findings of AIHA, led to the lym-
phoma workup. For patients who do not progress to lym-
phoma, one might speculate that rituximab (anti-CD20) 
given for the AIHA could have eradicated a malignant clone 
of B cells.
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